Key result
Icosapent ethyl reduced the composite of cardiovascular death, nonfatal MI, nonfatal stroke, coronary revascularization, or unstable angina by an absolute risk reduction of 4.8% compared to placebo.
Why the study?
Although REDUCE-IT demonstrated clinical benefit with icosapent ethyl, the mechanism of action of omega-3 fatty acids is not commonly discussed and risks including atrial fibrillation were observed.
Does icosapent ethyl reduce cardiovascular events in patients with hypertriglyceridemia and cardiovascular risk?
Does icosapent ethyl reduce cardiovascular events in patients with hypertriglyceridemia and cardiovascular risk?
Purified EPA ethyl ester provides cardiovascular benefits in high-risk patients through multiple pleiotropic mechanisms including improved endothelial function, reduced inflammation, and decreased platelet aggregation.
Answers are grounded in this paper and cite their sources.
May support icosapent ethyl in high-risk hypertriglyceridemia; leaves open optimal selection and long-term safety.
Heart disease continues to affect health outcomes globally, accounting for a quarter of all deaths in the United States. Despite the improvement in the development and implementation of guideline-directed medical therapy, the risk of adverse cardiac events remains substantially high. Historically, it has been debated whether omega-3 polyunsaturated fatty acids provide clinical benefit in cardiac disease. The recently published REDUCE-IT trial demonstrated a statistically significant absolute risk reduction of 4.8% in its primary endpoint (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina) with the use of icosapent ethyl, which is a highly purified eicosapentaenoic acid (EPA) ethyl ester. However, the mechanism of action of omega-3 fatty acids is not commonly discussed. Moreover, the use of EPA was not without risk, as the incidence of atrial fibrillation was increased along with a trend towards increased bleeding risk. Thus, our aim is to help explain the function of purified EPA ethyl ester, especially at the molecular level, which will ultimately lead to a better understanding of their clinically observable effects.
No takes yet. Share an insight, caveat, or question.
Sheikh et al. (2019) conducted a review in Hypertriglyceridemia with cardiovascular disease or diabetes (n=8,179). Icosapent ethyl vs. Placebo was evaluated on Composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina (ARR 4.8%, p=<0.001). Icosapent ethyl reduced the composite of cardiovascular death, nonfatal MI, nonfatal stroke, coronary revascularization, or unstable angina by an absolute risk reduction of 4.8% compared to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: